OncoMatch/Clinical Trials/NCT06258811
Neoadjuvant Immunochemotherapy for LAOSCC
Is NCT06258811 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies albumin paclitaxel, cispatin, tislelizumab for oral squamous cell carcinoma.
Treatment: albumin paclitaxel, cispatin, tislelizumab — To evaluate the prognostic efficacy of neoadjuvant immunochemotherapy with tislelizumab, albumin paclitaxel and cisplatin followed by radical surgery and adjuvant therapy compared with standard therapy for patients with locally advanced and resectable oral squamous cell carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage III, IVA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anticancer treatment
Unresolved grade 2 (CTCAE 5.0) or higher toxic reactions caused by previous anticancer treatments
Cannot have received: radiation therapy
Known history of radiation to head and neck
Cannot have received: immunology-based treatment
Patients receiving immunology-based treatment for any reason
Lab requirements
Blood counts
WBC >3,000/mm3, hemoglobin >8 g/L, platelets >80,000/mm3
Kidney function
Serum creatinine <1.5x ULN
Liver function
ALAT/ASAT <2.5x ULN and bilirubin <1.5x ULN
Blood routine: white blood cells (WBCs) >3,000/mm3, hemoglobin >8 g/L, platelets >80,000/mm3; Liver function: ALAT/ASAT <2.5x ULN and bilirubin <1.5x ULN; Renal function: Serum creatinine <1.5x ULN; Coagulation function: INR, PT, APTT <1.5x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify